Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management
Authors:
- Sumera I. IlyasSISumera I. Ilyas
- Gregory J. GoresGGGregory J. Gores
- 1 November 2015
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 13 (12) , 2152-2165
Abstract
No abstract availableKeywords
Funding Information
- Mayo Foundation for Medical Education and Research
- American Liver Foundation
- National Institutes of Health (DK59427, T32DK007198)
This publication has 99 references indexed in Scilit:
- Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and ManagementGastroenterology, 2013
- Oxysterols are allosteric activators of the oncoprotein SmoothenedNature Chemical Biology, 2012
- A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary stricturesBritish Journal of Cancer, 2011
- Cancer surveillance in patients with primary sclerosing cholangitisHepatology, 2011
- Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract CancerJournal of Clinical and Experimental Hepatology, 2011
- Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cellsHepatology, 2010
- TRAIL treatment provokes mutations in surviving cellsOncogene, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Death receptor 5 mediated-apoptosis contributes to cholestatic liver diseaseProceedings of the National Academy of Sciences, 2008
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003